Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ( H, p& z8 ]& R$ e2 S! x3 [) B
) u- U( U+ U2 Y5 ?5 e' S' z
# X. R+ z c0 c( s, _Sub-category:* D% e4 O3 k# i; } v
Molecular Targets
2 M3 x' E* F2 O2 b$ t( J) j$ M. U
% T- q- ]# u* q$ l1 j0 |" P0 o. T k4 y& r( \4 Z
Category:! G# ? z& `& Y1 g8 F7 g
Tumor Biology
0 t& H# m8 J7 \" B o( x. r, A
; Y- \8 [. H# Q9 Q$ i
' h2 u. }1 K3 ]/ lMeeting:
: k2 b; X# P7 _' k7 i4 C9 K2011 ASCO Annual Meeting
. g- F0 ]9 g3 y, n8 X4 z) u. q4 S
E3 ]7 b( v* o K7 h6 ~2 q, G% Z' J0 W/ ^# r
Session Type and Session Title:
# n _& B8 X' C7 r, ^ @, BPoster Discussion Session, Tumor Biology
* w+ G# w2 o* @% V: u% M/ W( u6 u) X
9 n3 V, l* m1 _$ F
Abstract No:
3 G( u* H' G+ Z10517 % J5 G9 b) R+ w: D4 Y6 O
( _. e3 d' g* W2 z) v) x" \
% a+ ^1 @3 Z9 X; `. aCitation:
0 f0 d4 G2 C' \: F4 o2 PJ Clin Oncol 29: 2011 (suppl; abstr 10517)
+ U7 j+ \2 J2 ?! ?% J* Z+ c+ C! m2 ~- ]. e5 T
( e* j4 j( [: f) [4 O9 e
Author(s):) N/ k" ~( }+ b% i' t2 j5 o, S( ^
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China - D$ C3 [( J) T4 U
) i8 w- l9 T8 f& T5 }' _) t* r. p5 F( @
- G. N0 s- `) c9 V1 N& CAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
* v, c2 G& X% t7 L2 J" `' q+ X0 V3 V8 W0 o
Abstract Disclosures
+ g# F# c: C; R$ @& S6 O& w0 m: t' ]/ A4 o- Q* i1 I
Abstract:. e! t/ E2 [5 T% a% y- v9 E+ H
; z2 }/ ?: k6 [. S' p, m$ P
" f/ [3 n$ o: y; _Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
+ w1 n- k3 P) a; Y1 P: `
5 j. j- |8 u0 U# t; M 3 N! {5 m+ j& x0 `' `: v
|
7 Y0 S+ x5 i8 h* {& b) ~! W
显身卡
